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bjectives This study sought to understand the total weight of evidence regarding outcomes in
oronary artery bypass grafting (CABG) versus percutaneous coronary intervention (PCI) in unpro-
ected left main coronary artery (ULMCA) stenosis.
ackground Following a diagnosis of signiﬁcant ULMCA stenosis in an individual that is a candidate
or surgery, CABG is recommended by the American College of Cardiology/American Heart Associa-
ion guidelines, whereas PCI is not recommended (Class III).
ethods Databases were searched for clinical studies that reported outcomes after PCI and CABG
or the treatment of ULMCA stenosis. Ten studies were identiﬁed that included a total of 3,773 patients.
esults Meta-analysis showed that death, myocardial infarction, and stroke (major adverse cardio-
ascular or cerebrovascular events) were similar in the PCI- and CABG-treated patients at 1 year
odds ratio [OR]: 0.84 [95% conﬁdence interval: 0.57 to 1.22]), 2 years (OR: 1.25 [95% CI: 0.81 to
.94]), and 3 years (OR: 1.16 [95% CI: 0.68 to 1.98]). Target vessel revascularization was signiﬁcantly
igher in the PCI group at 1 year (OR: 4.36 [95% CI: 2.60 to 7.32]), 2 years (OR: 4.20 [95% CI: 2.21 to
.97]), and 3 years (OR: 3.30 [95% CI: 0.96 to 11.33]). There was no difference in mortality in PCI-
ersus CABG-treated patients at 1 year (OR: 1.00 [95% CI: 0.70 to 1.41]), 2 years (OR: 1.27 [95% CI:
.83 to 1.94]), and 3 years (OR: 1.11 [95% CI: 0.66 to 1.86]).
onclusions Our analysis reveals no difference in mortality or major adverse cardiovascular or cere-
rovascular events, for up to 3 years, between PCI and CABG for the treatment of ULMCA stenosis.
owever, PCI patients had a signiﬁcantly higher risk of target vessel revascularization. In selected
atients with ULMCA stenosis, PCI is emerging as an acceptable option. (J Am Coll Cardiol Intv
009;2:739–47) © 2009 by the American College of Cardiology Foundation
rom *Cedars-Sinai Heart Institute, Cedars Sinai Medical Center, and †Department of Biostatistics, University of California,
os Angeles School of Public Health, Los Angeles, California.anuscript received February 20, 2009; revised manuscript received April 30, 2009, accepted May 7, 2009.
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740ignificant left main stenosis is found in approximately 4% of
atients undergoing diagnostic coronary angiography (1) and
as been shown to portend high mortality (2–6). Trials
omparing coronary artery bypass grafting (CABG) to medical
herapy have shown a mortality reduction in patients with
hese lesions (7–9). A meta-analysis of all available trials has
olidified CABG as the gold standard for the treatment of
nprotected left main disease (9). According to published
uidelines, it is a class I indication to perform CABG for
ignificant unprotected left main coronary artery (ULMCA)
tenosis in patients that are suitable for surgery (10).
Since these original trials were published, percutaneous
oronary intervention (PCI) has emerged as an alternative to
ABG for the treatment of coronary artery disease. Still, in
atients that are CABG candidates, PCI is designated a
lass III indication (10) and is a class IIa indication in
nsuitable candidates for CABG (11).
Advances in PCI technology and technique have led
ome interventionalists to operate outside these guidelines.
In fact, a recent meta-analysis of
reports of unprotected left main
stenting demonstrated reason-
able outcomes (12), leading to
the conclusion that left main
stenting is at least feasible.
But how does PCI compare
with CABG? Although some
centers have published matched
data (13,14) a meta-analysis is
important because single-center
studies are typically underpow-
ered to detect differences in
mortality. To understand the
risk in unprotected left main pa-
tients, we performed a meta-
nalysis of all available PCI versus CABG studies.
ethods
earch strategy. The meta-analysis considered studies that
ompared PCI with CABG for unprotected left main
tenosis.
Candidate studies were identified by searching BioMed
entral, ClinicalTrials.gov, Google Scholar, and PubMed
nd presentations of any randomized datasets at the major
eetings of the American Heart Association, the American
ollege of Cardiology, and Trans-Catheter Therapeutics.
ll searches covered the period January 2004 through
ecember 2008. Key words used included “unprotected left
ain,” “PCI,” “CABG,” and “comparison.” We also pe-
used the bibliographies of retrieved articles and relevant
eviews to identify further relevant studies.
Studies were included if they met the following criteria: 1)
bbreviations
nd Acronyms
ABG  coronary artery
ypass grafting
ACCE  major adverse
ardiac and cerebrovascular
vents
I  myocardial infarction
R  odds ratio
CI  percutaneous
oronary intervention
VR  target vessel
evascularization
LMCA  unprotected left
ain coronary arterynrestricted comparison of cohorts of CABG and PCI for the preatment of ULMCA stenosis; 2) a minimum of 1-year
ollow-up; 3) documentation of survival and major adverse
ardiac and cerebrovascular events (MACCE); 4) more than
0 patients in each cohort along with reporting of risk scores;
) publication in a peer-reviewed journal, or presentation of
andomized datasets at a major national cardiology meeting.
utcomes. The primary end point was the odds ratio for
ortality after PCI or CABG, up to 3 years. Secondary end
oints were the odds ratio of MACCE (death, myocardial
nfarction [MI], and stroke) and target vessel revasculariza-
ion (TVR) after the procedure.
ata. From each study, we extracted patient characteristics,
tudy design, and outcomes at each of years 1, 2, and 3 after
reatment of ULMCA stenosis. When possible, actual
robabilities of mortality and death after 1, 2, or 3 years
ollowing PCI or CABG were used to calculate odds ratios
14 –20). Alternatively, probabilities of mortality or
ACCE were estimated from published Kaplan-Meier
urvival curves (13,21,22). Sample sizes at risk at each year
ere taken from the reports, or in 1 case (18), estimated
sing reported CABG/PCI group-specific means and vari-
nces of follow-up times and a log-normal model for actual
ample at risk (18). We reanalyzed our own dataset to
stablish Kaplan-Meier curves and probabilities of mortality
nd MACCE, which were used to calculate odds ratios
14). We did not include adjusted odds ratios as only 1 study
eported this data (15), and only 4 others reported hazard
atios (13,14,17,21). When possible, we also extracted TVR
rom the total MACCE events and reported this outcome
s a separate measure. When MACCE was reported, all but
report defined MACCE to include death, MI, stroke, and
VR. One report did not include stroke, and we did not
nclude this in our MACCE analysis (21). Another dataset
id not report total MACCE (17). The data from our
nstitution was reanalyzed up to September 2008 (14).
tatistical analysis. Each study is summarized by the odds
atio (OR) for CABG against PCI. The ORs were com-
ined across studies using DerSimonian-Laird random
ffects model and were pre-specified (23,24). We also
ombined odds ratios with the fixed effects model using the
antel-Haenszel model. We performed the Woolf’s test
or heterogeneity. Sensitivity analyses were performed omit-
ing a single study at a time. Analysis was conducted in R (R
evelopment Core Team 2007) package rmeta version
.14. All p values were 2-tailed and p 0.05 was considered
ignificant (25).
esults
haracteristics of the included studies. We identified 13
ligible studies (13–22,26–28) that compared PCI and
ABG cohorts for the treatment of ULMCA coronary
tenosis. Three of these studies were excluded because of: 1)
robable overlap with the institution’s previous report (27);
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741) subgroup analysis (27,28); and 3) 30 PCI patients were
tudied (26). Figure 1 demonstrates our search process.
haracteristics of each study are shown in Table 1. A total
f 3,773 patients were studied with 2,114 receiving CABG
nd 1,659 receiving PCI. There were 354 PCI patients who
nderwent bare-metal stent implantation and 1,305 PCI
Non-relevant studies 
(n = 6975)
Excluded (n = 310)
1. Lack of comparison of 
PCI/CABG cohorts  -307 
2. < 30 patients included -1
3. Subgroup analysis of 
left main patients -2
Pub Med
Google 
Scholar
B
C
Studies revi
Figure 1. Search Process Algorithm
Flow chart demonstrating the resulting 10 studies that were analyzed. Subgro
founding. ACC  American College of Cardiology; AHA  American Heart Ass
intervention; TCT  Trans-Catheter Therapeutics.
Table 1. Study Characteristics
Study (Ref. #) CABG, n LIMA to LAD, % PCI, n DES
Brener et al. (18) 190 99 97 5
Buszman et al. (16) 53 81 52 3
Chieffo et al. (15) 142 NA 107 10
Makikallio, et al. (19) 238 NA 49 10
Palmerini et al. (21) 154 94.2 157 6
Sanmartin et al. (22) 245 98 96 10
SYNTAX left main* (20) 348 NA 357 10
Seung et al. (13) 542 “Whenever possible” 542 7
White et al.† (14) 67 96.4 67 10
Wu et al. (17) 135 NA 135 4
Total 2,114 1,659
*Left main subset of the SYNTAX (Synergy Between Percutaneous Coronary Intervention With TaxuBMS bare-metal stent(s); CABG coronary artery bypass grafting; DESdrug-eluting stent(s); LAD left aatients who underwent drug-eluting stent implantation.
f the total, 3,325 had more than 1 year of follow-up. The
verall internal validity was moderate and is illustrated in
able 2. Of the 10 studies, 3 matched the treatment cohorts
sing EuroSCORE (15,18,22), 2 randomized patients to
reatment group (16,20), and 3 used propensity scores to
Articles requiring full 
text/abstract review (n = 320)
Articles meeting inclusion 
criterion(n = 10)
ed 
al
Clinical 
Trials.gov
ACC/AHA/
TCT
 (n = 7294)
left main patients were not included due to the possibility of added con-
n; CABG  coronary artery bypass grafting; PCI  percutaneous coronary
BMS, % Unadjusted Risk
Method of
Adjustment Years
38 Matched on EuroSCORE Unneeded 1997–2006
65 Randomized, same risk Unneeded 2001–2004
0 CABG slightly higher Propensity score
adjusted
2002–2004
0 PCI group with a signiﬁcantly
higher EuroSCORE
(7.7 vs. 5.2)
Unmatched,
unadjusted
2005–2007
40 PCI higher. PCI group had a
signiﬁcantly higher
Parsonett score
(17% vs. 13%)
Propensity score
adjusted
2002–2005
0 CABG slightly higher Propensity score
adjusted
2000–2005
0 Randomized, same risk Unneeded 2006–2008
25 Propensity score matched Unneeded 2000–2006
0 Propensity score matched Unneeded 2003–2007
59 Propensity score matched Unneeded 2000–2004
ardiac Surgery) trial. †Our data updated to October 2008.io M
entr
ewed
ups of
ociatio, %
7
5
0
0
0
0
0
5
0
1
s and Cnterior descending; LIMA left internalmammary artery; PCI percutaneous coronary intervention.
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742uarantee like-to-like comparisons (13,14,17). We also
ncluded the left main subset from the recently concluded
YNTAX (Synergy Between Percutaneous Coronary Inter-
ention With Taxus and Cardiac Surgery) trial (20). In 2
tudies (19,21), the baseline characteristics of the groups
ere different. One of these studies (21) used the propensity
core to adjust for this difference. In these studies, the PCI
roup had higher risk characteristics than the CABG group
s evidenced by a significantly higher Parsonnet (29) score
r EuroSCORE value (30).
utcome
eath. The OR of the risk of death in the PCI group
ompared with the CABG group in each study, at the 1-,
Table 2. Internal Validity
Study (Ref. #)
Prospective
Design
Multicenter
Enrollment
Selection
Bias
Brener et al. (18) No No B
Buszman et al. (16) Yes Yes A
Chieffo et al. (15) No No A
Makikallio et al. (19) No No C
Palmerini et al. (21) Yes No A
Sanmartin et al. (22) No No A
SYNTAX left main* (20) Yes Yes A
Seung et al. (13) Yes Yes A
White et al.† (14) No No A
Wu et al. (17) No No B
This was performed by 3 independent reviewers. The overall bias of the combined studies was cons
With Taxus and Cardiac Surgery) trial. †Our data updated to October 2008.
A risk of bias is low; B risk of bias is moderate; C risk of bias is high; D incomplete report
Table 3. Estimated OR of Death in the PCI Group Versus the CABG Group
Study (Ref. #)
Year 1
OR (95% CI)
Brener et al. (18) 0.88 (0.26–2.99)
Buszman et al. (16) 0.24 (0.03–2.23)
Chieffo et al. (15) 0.43 (0.11–1.61)
Makikallio et al. (19) 0.36 (0.08–1.58)
Palmerini et al. (21) 0.27 (0.53–3.02)
Sanmartin et al. (22) 0.71 (0.20–2.53)
SYNTAX left main* (20) 0.97 (0.47–2.02)
Seung et al. (13) 1.13 (0.58–2.19)
White et al.† (14) 1.36 (0.33–5.55)
Wu et al. (17) 3.06 (0.99–9.45)
Summary (random effects) 1.00 (0.70–1.41)
Summary (ﬁxed effects) 0.97 (0.71–1.33)
Test for heterogeneity chi-square (9)  9.67, p  0.38
Est RE Var  0.02
Both fixed effects and random effects analysis were performed. *Left main subset of the SYNTAX
updated to October 2008. The chi-square test and p value are for the Woolf test of heterogeneity.CI confidence interval; Est RE Var estimated random effects variance; OR odds ratio; other abbrev-, and 3-year time points, is reported in Table 3. There
as no evidence for heterogeneity of treatment effect
mong the studies for death at the 1-, 2-, or 3-year time
oints.
The overall OR (95% confidence interval) of mortality
howed no difference between PCI and CABG at 1 year
OR: 1.00 [0.70 to 1.41]), at 2 years (OR: 1.27 [0.83 to
.94]), at 3 years (OR: 1.11 [0.66 to 1.86]) (Table 3 and
igure 2).
ACCE. Table 4 and Figure 3 summarize MACCE without
VR, for each study for PCI and CABG patients, at the 1-,
-, and 3-year time points. Table 5 and Figure 4 summarize
he TVR results. Meta-analysis did not detect a difference in
ACCE, excluding TVR (death, MI, and stroke), in PCI-
ersus CABG-treated patients at 1 year (OR: 0.84 [0.57 to
erformance
Bias
Attrition
Bias
Detection
Bias
Multivariate Adjustment for
Potential Confounders
B D B Probably adequate
B A B Probably adequate
B A B Probably adequate
B D B Probably adequate
B A B Probably adequate
B A B Probably adequate
B A B Probably adequate
B A B Probably adequate
B A B Probably adequate
B D B Probably adequate
oderate. *Left main subset of the SYNTAX (Synergy Between Percutaneous Coronary Intervention
h Year
Year 2
OR (95% CI)
Year 3
OR (95% CI)
1.08 (0.38–3.1) 1.42 (0.56–3.63)
1.10 (0.29–4.2)
0.93 (0.22–3.97) 0.81 (0.07–9.35)
1.17 (0.65–2.12) 1.01 (0.54–1.92)
1.62 (0.15–17.05)
3.50 (0.89–13.80)
1.27 (0.83–1.94) 1.11 (0.66–1.86)
1.28 (0.84–1.94) 1.11 (0.66–1.85)
chi-square (5)  2.52, p  0.77 chi-square (2)  0.41, p  0.81
Est RE Var  0.0 Est RE Var  0.0
y Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) trial. †Our dataP
ideredmat Eac
(Synergiations as in Table 1.
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743.22], 2 years (OR: 1.25 [0.81 to 1.94], or at 3 years (OR: 1.16
0.68 to 1.98]). There was a statistically significant difference in
VR favoring CABG at year 1 (OR: 4.36 [2.60 to 7.32]) and
ear 2 (OR: 4.20 [2.21 to 7.97]). The effect was borderline not
ignificant in year 3 (OR: 3.30 [0.96 to 11.33]).
We were not able to separate TVR data from MACCE
rom the study by Brener et al. (18), so this study did not
ontribute to this MACCE meta-analysis. Also, the study by
almerini et al. (21) did not report stroke and thus we did not
nclude this set in our MACCE (death, MI, and stroke)
nalysis.
There was no evidence of interstudy heterogeneity of treat-
Brener
Buszman
Chieffo
Mäkikallio
Palmerini
Sanmartin
Seung
SYNTAX_LM
White
Wu
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Figure 2. Odds Ratio of Mortality Following Treatment for ULMCA Disease in
PCI Versus CABG Patients
Odds ratio of mortality (with conﬁdence intervals) following treatment for
unprotected left main coronary artery (ULMCA) disease after 1, 2, and 3 years.
Year 1: 1,393 PCI patients and 1,932 CABG patients; year 2: 528 PCI patients
and 890 CABG patients; and year 3: 263 PCI patients and 578 CABG patients.
Abbreviations as in Figure 1.ent effect for years 1, 2, and 3 for death, MI, and stroke (year m: chi-square test: 9.96, p  0.18, estimated random effects
ariance: 0.08; year 2: chi-square test: 0.71, p 0.7, estimated
andom effects variance: 0; year 3: chi-square test: 1.47,
 0.48, estimated variance: 0). There also was no evidence of
nterstudy heterogeneity for TVR only (year 1: chi-square test:
3.28, p  0.66, estimated random effects variance: 0; year 2:
hi-square test: 3.69, p  0.30, estimated random effects
ariance: 0.09; year 3: chi-square test: 3.53, p 0.55, estimated
andom effects variance: 0).
iscussion
he most important finding in our meta-analysis of left
Buszman
Chieffo
Mäkikallio
Sanmartin
Seung
SYNTAX_LM
White
Summary
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Figure 3. Odds Ratio of MACCE in PCI Versus CABG Patients
Odds ratio of major adverse cardiac and cerebrovascular events (MACCE)
(death, myocardial infarction, and stroke) in PCI patients versus CABG
patients after 1, 2, and 3 years. Year 1: 1,239 PCI patients and 1,614 CABG
patients; year 2: 432 PCI patients and 652 CABG patients; and year 3: 236
PCI patients and 451 CABG patients. Abbreviations as in Figure 1.ain stenting versus CABG is that in a real-world appli-
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744ation among 3,000 patients, there was no difference in
ortality between the 2 treatment options at 1, 2, or 3 years
f follow-up. In addition to the absence of difference in
ortality, we also found that the combined end point of
eath, MI, and stroke was similar in the 2 treatment groups.
f additional note is that 79% of the PCI patients received
rug-eluting stents, without succumbing to a higher mor-
ality than in patients treated with CABG. This is despite
he recent controversy involving stent thrombosis (31).
In contrast to the mortality, MI, and stroke results, TVR
as significantly higher in the PCI group. This result is
onsistent with all comparisons of PCI to CABG and
eflects the restenosis rate associated with PCI (32). The
ifference might be influenced by the 21% of patients with
are-metal stents in the meta-analysis population, given
hat bare-metal stent implantation has higher TVR rates in
arge datasets (33). Regardless, it is clear from this analysis
Table 4. Estimated OR of Death, MI, and Stroke in the PCI Group Versus t
Study (Ref. #)
Year 1
OR (95% CI)
Buszman et al. (16) 1.37 (0.58–3.23)
Chieffo et al. (15) 0.53 (0.18–1.56)
Makikallio et al. (19) 0.31 (0.09–1.06)
Sanmartin et al. (22) 0.48 (0.18–1.30)
SYNTAX left main* (20) 0.74 (0.43–1.28)
Seung et al. (13) 1.02 (0.57–1.84)
White et al.† (14) 1.70 (0.73–3.97)
Summary (random effects) 0.84 (0.57–1.22)
Summary (ﬁxed effects) 0.82 (0.62–1.09)
Test for heterogeneity chi-square (6)  9.67, p  0.18
Est RE Var  0.08
Bothfixedeffects and randomeffects analysiswereperformed. *Leftmain subset of the SYNTAX trial.
MImyocardial infarction; other abbreviations as in Tables 1 and 3.
Table 5. Estimated OR of TVR in the PCI Group Versus the CABG Group at
Study (Ref. #)
Year 1
OR (95% CI)
Buszman et al. (16) 3.89 (1.30–11.68)
Chieffo et al. (15) 6.69 (2.43–18.40)
Makikallio et al. (19) 2.49 (0.44–13.99)
Sanmartin et al. (22) 6.68 (1.27–35.02)
SYNTAX left main* (20) 1.94 (1.14–3.29)
Seung et al. (13) 6.49 (2.96–14.23)
White et al.† (14) 3.10 (0.85–11.34)
Wu et al. (17) 13.77 (3.46–54.82)
Summary (random effects) 4.36 (2.60–7.32)
Summary (ﬁxed effects) 3.84 (2.77–5.33)
Test for heterogeneity chi-square (9)  9.67, p  0.38
Est RE Var  0.02
Bothfixedeffects and randomeffects analysiswereperformed. *Leftmain subset of the SYNTAX trial.TVR target vessel revascularization; other abbreviations as in Tables 1 and 3.hat even with drug-eluting stents, there is a statistically
igher TVR rate.
Takagi et al. (34) recently presented a meta-analysis of
CI versus CABG in unprotected left main patients. This
tudy identified only 6 studies. One study (35) included old
ata from our group, of which we have presented updated
ata here (14). Two of the studies (21,27) likely represent
verlapping data. Finally, their data does not include the
atients from 2 other studies (17,19) and the recently
resented randomized left main subset of the SYNTAX
rial (20). Given these reasons, we feel our analysis is more
nclusive of the data that is currently available.
The idea that PCI treatment of left main disease, as
ompared with CABG, impedes treatment of moderate
roximal lesions and thereby increases risk was not borne
ut in our data up to 3 years. Thus, the equivalence in death,
I, and stroke along with a higher rate of TVR with PCI
BG Group at Each Year
Year 2
OR (95% CI)
Year 3
OR (95% CI)
1.05 (0.33–3.30) 1.24 (0.21–7.31)
1.16 (0.67–2.00) 1.01 (0.56–1.84)
1.81 (0.68–4.82) 2.82 (0.60–13.27)
1.25 (0.81–1.94) 1.16 (0.68–1.98)
1.25 (0.81–1.94) 1.16 (0.68–1.96)
chi-square (2)  0.71, p  0.70 chi-square (2)  1.47, p  0.48
Est RE Var  0.0 Est RE Var  0.0
ataupdated toOctober 2008. The chi-square test andpvalue are for theWoolf test of heterogeneity.
Year
Year 2
OR (95% CI)
Year 3
OR (95% CI)
3.87 (0.75–19.88) 5.89 (0.57–60.59)
5.13 (2.50–10.54) 5.40 (2.37–12.31)
1.55 (0.44–5.51) 0.71 (0.10–5.16)
8.85 (2.08–37.65)
4.20 (2.21–7.97) 3.30 (0.96–11.33)
4.35 (2.54–7.44) 4.01 (2.01–7.98)
chi-square (9)  9.67, p  0.38 chi-square (9)  9.67, p  0.38
Est RE Var  0.02 Est RE Var  0.02
ataupdated toOctober 2008. The chi-square test andpvalue are for theWoolf test of heterogeneity.he CA
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745uggests that the choice between the 2 treatment options
an be defined by both the individual clinical presentation
nd the practical tradeoff between differences in recovery
eriod and repeat revascularization.
The details of our meta-analysis also deserve iteration.
e only analyzed datasets that compared left main stenting
o a cohort of CABG for left main disease. In 2 of the 10
atasets (19,21) we used, substantially higher risk PCI
atients were compared with lower risk CABG. The other
datasets compared matched groups, which suggests that
he operators in these programs felt that left main PCI does
ot portend worse outcomes. This view, different from the
uidelines, may reflect the influence of a number of recently
ublished datasets (12,36,37) reporting favorable outcomes
n left main PCI, even though most of these reports do not
ompare PCI and CABG outcomes. One study (17), a New
Figure 4. Odds Ratio of TVR in PCI Versus CABG Patients
Odds ratio of target vessel revascularization (TVR) in PCI patients versus
CABG patients at 1, 2, and 3 years. Year 1: 1,240 PCI patients and 1,692
CABG patients; year 2: 417 PCI patients and 699 CABG patients; and year 3:
211 PCI patients and 447 CABG patients. Abbreviations as in Figure 1.ork state data registry, reported results that differed from rhe other 9 studies and from the conclusions of the
eta-analysis. The difference may be due to the inclusion of
ata from many laboratories in the New York registry, as
pposed to the single high-volume centers represented in
ther reports. Inclusion of this dataset makes our meta-
nalysis less susceptible to publication bias given the mark-
dly different results reported.
We included in our analysis data from the recently
ompleted SYNTAX trial (20). This trial contains the
argest dataset to date comparing left main PCI and CABG.
his data has not been analyzed fully given that it was a
ubset within the context of a larger group of patients
multivessel disease and left main stenosis patients). The
tudy was not powered to detect statistically significant
ifferences between these groups. However we can make
nferences by including this data in a meta-analysis. Also,
ur test of heterogeneity did not detect much difference
etween studies, suggesting that the SYNTAX trial (20)
nd LEMANS (Study of Unprotected Left Main Stenting
ersus Bypass Surgery) trial (16) (the only 2 randomized
atasets) reflect the real-world data described in the other
atasets. The absence of difference supports the notion that
eal-world data is consistent with current randomized trials
or this particular analysis.
Although this meta-analysis represents 3,000 patients
ith general consistency between randomized and retro-
pective patients, the choice of therapy may best be deter-
ined by factors specific to the individual patient and
perator experience. The SYNTAX score (38) recently has
een developed to guide operators in this regard. This score
escribes the coronary and clinical complexity of a patient
nd might help us identify the most appropriate therapy
PCI vs. CABG) on an individual level.
tudy limitations. Our study is subject to the usual limita-
ions of meta-analyses, namely variation in study design and
ublication bias. The meta-analysis is also dominated by the
orean MAIN-COMPARE (Revascularization for Unpro-
ected Left Main Coronary Artery Stenosis: Comparison of
ercutaneous Coronary Angioplasty Versus Surgical Revas-
ularization) registry (13), which accounts for approximately
0% of the PCI patients in the synthesis. However, their
esults are consistent with the other publications and are
imilar based on heterogeneity. An additional caveat is that
ith the exception of the New York Registry (17), data
ame from highly experienced centers, with 40 ULMCA
CI cases performed. Therefore, similar results may not be
btained by less experienced operators. A final limitation is
he absence of adequate published comparative data for the
hird therapeutic option, medical therapy. Percutaneous
oronary intervention has not been compared with medical
herapy alone, but CABG has been shown to be superior to
edical therapy. Further, the follow-up in this analysis is up
o 3 years. The long-term durability of PCI versus CABG
emains undetermined and will require longer follow-up.
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746lso, it would be ideal to perform statistical pooling of
djusted risk estimates of odds ratios or hazard ratios.
owever, only 5 of the 10 studies reported adjusted risk
atios that could be combined, and over one-third of the
atients would not be included. For this reason, we did not
nclude this analysis.
onclusions
he notion that CABG is the only option for left main
tenosis for the prevention of death and MI, at least up to 3
ears, can be re-evaluated. More importantly, we suggest
hat a multidisciplinary management approach among sur-
eons, interventionalists, cardiologists, and primary care
hysicians should occur with patients who have significant
eft main disease. Then, based on patient and angiographic
actors, PCI can be considered a reasonable choice in
elected patients. Our results suggest that the current
merican College of Cardiology/American Heart Associa-
ion guidelines regarding left main PCI (10) should be
evisited.
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